PhytoCeutica

PhytoCeutica develops prescription botanical drugs based on traditional Chinese medicine, focusing on oncology supportive care. Its lead candidate, PHY906/YIV906, has shown promise in reducing chemotherapy-induced toxicities and enhancing efficacy when combined with standard chemotherapies in colorectal, liver, and pancreatic cancers. Over approximately ten years of research—including five clinical studies involving about 150 subjects—PHY906 demonstrated the ability to improve patient outcomes without affecting the pharmacokinetics of chemotherapeutic agents. The company’s proprietary PhytomicsQC platform ensures product consistency across batches.